Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

darolutamide 1Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × High-Risk Localized Prostate Cancer × Clear all
NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

NCT07550517 2026-04-24

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡